NmVac4-DT

NmVac4-DT is a quadrivalent conjugate vaccine candidate developed by the Finlay Institute of Vaccines (Instituto Finlay de Vacunas) in Cuba for the prevention of invasive meningococcal disease. It targets *Neisseria meningitidis* serogroups A, C, W-135, and Y. The vaccine utilizes capsular polysaccharides from each of the four serogroups, which are individually conjugated to a diphtheria toxoid (DT) carrier protein. This conjugation process is designed to elicit a T-cell dependent immune response, which is more robust and provides longer-lasting protection compared to pure polysaccharide vaccines, especially in young children. The development of NmVac4-DT aims to provide an affordable and effective alternative for controlling meningococcal outbreaks and endemic disease in regions such as the African meningitis belt and Latin America.

Other names

Quadrivalent meningococcal (A, C, W, Y) conjugate vaccineMeningococcal ACWY-DT vaccine